Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers

by Wanda Rich
0 comments
2024 03 18T145805Z 4 LYNXNPEK2H0C7 RTROPTP 4 HEALTH CORONAVIRUS VACCINES ASTRAZENECA

AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers

(Reuters) – Drugmaker AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products at $35 per month in the United States, following a similar move by rival Boehringer Ingelheim earlier in the month.

High drug prices in the United States have been the subject of growing political scrutiny for years. Senator Bernie Sanders and other lawmakers in January criticized the top four manufacturers of inhalers sold in the U.S. — AstraZeneca, Boehringer, Teva Pharmaceuticals and GlaxoSmithKline — over the product’s high prices.

In letters sent to these companies, the lawmakers said they were launching an investigation into what they termed “extremely high prices” for inhalers for asthma and chronic obstructive pulmonary disease in the U.S. versus other countries.

UK-based AstraZeneca’s cap, effective June 1, would apply to its entire respiratory products portfolio, including inhalers such as Airsupra, Bevespi Aerosphere and Breztri Aerosphere, and would be applicable for patients who are uninsured or underinsured.

Breztri Aerosphere costs $645 in the U.S. but $49 in the UK, according to the letter by Sanders and other lawmakers.

“We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone,” AstraZeneca CEO Pascal Soriot said. “It is critical that Congress bring together key stakeholders to help reform the healthcare system so patients can afford the medicines they need.”

Boehringer had also said it would cap out-of-pocket costs for its inhaler products for chronic lung disease and asthma to $35 per month, starting June 1.

The letter said Boehringer’s Combivent Respimat costs $489 in the U.S. but just $7 in France.

Sanofi and Eli Lilly had also announced last year that they would cap insulin prices at $35 a month.

(Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar)